rs12245, rs12587, rs9266, rs1137282, rs61764370, and rs712 of KRAS oncogene are characterized in the 3′UTR. The study highlights the important role of these polymorphisms playing in the susceptibility, oxaliplatin-based chemotherapy sensitivity, progression, and prognosis of CRC. Improved multiplex ligation detection reaction (iMLDR) technique is used for genotyping. An unconditional logistic regression model was used to estimate the association of certain polymorphism and CRC risk. The Kaplan–Meier method, log-rank test, and Cox regression model were used to evaluate the effects of polymorphisms on survival analysis. Results demonstrated that TT genotype and T allele of rs712 were associated with the increased risk of CRC; the patients with GG genotype and G allele of rs61764370 had a shorter survival and a higher risk of relapse or metastasis of CRC. Our studies supported the conclusions that rs61764370 and rs712 polymorphisms of the KRAS are functional and it may play an important role in the development of CRC and oxaliplatin-based chemotherapy efficiency and prognosis of CRC.
KRAS Polymorphisms Survival Colorectal cancer
This is a preview of subscription content, log in to check access.
These work successfully completed were supported by Genesky Biotechnologies, Inc. (Shanghai, China) and all the volunteer participants.
Compliance with ethical standards
This work was financially supported by the State Natural Sciences Foundation Projects of China (No. 81101679), the Joint Project of Department of Technology of Luzhou, Sichuan and Luzhou Medical College (No. 2013LZLY-J44, No. 14JC0091), Fund Project of Department of Education of Sichuan Province (No. 13ZB0272), and Project of Department of Health of Sichuan Province (No. 120376).
Theodoratou E, Montazeri Z, Hawken S, Allum GC, Gong J, et al. Systematic meta-analyses and field synopsis of genetic association studies in colorectal cancer. J Natl Cancer Inst. 2012;104:1433–57.CrossRefPubMedGoogle Scholar
Bonfrate L, Altomare DF, Di Lena M, Travaglio E, Rotelli MT, et al. MicroRNA in colorectal cancer: new perspectives for diagnosis, prognosis and treatment. J Gastrointestin Liver Dis. 2013;22:311–20.PubMedGoogle Scholar
Altomare DF, Di Lena M, Giuratrabocchetta S. MicroRNA: future perspectives in colorectal cancer. Color Dis. 2012;14:133–4.CrossRefGoogle Scholar
Akao Y, Nakagawa Y, Naoe T. let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull. 2006;29:903–6.CrossRefPubMedGoogle Scholar
Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, et al. RAS is regulated by the let-7 microRNA family. Cell. 2005;120:635–47.CrossRefPubMedGoogle Scholar
Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, et al. A SNP in a let-7 microRNA complementary site in the KRAS 3′UTR increases non-small cell cancer risk. Cancer Res. 2008;68:8535–40.CrossRefPubMedPubMedCentralGoogle Scholar
Paranjape T, Heneghan H, Lindner R, Keane FK, Hoffman A, et al. A 3′-untranslated region KRAS variant and triple-negative breast cancer: a case–control and genetic analysis. Lancet Oncol. 2011;12:377–86.CrossRefPubMedPubMedCentralGoogle Scholar
Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004;64:3753–6.CrossRefPubMedGoogle Scholar
Christensen BC, Moyer BJ, Avissar M, Ouellet LG, Plaza SL, et al. A let-7 microRNA-binding site polymorphism in the KRAS 3′UTR is associated with reduced survival in oral cancers. Carcinogenesis. 2009;30:1003–7.CrossRefPubMedPubMedCentralGoogle Scholar
Pan XM, Sun RF, Li ZH, Guo XM, Zhang Z, et al. A let-7 KRAS rs712 polymorphism increases colorectal cancer risk. Tumour Biol. 2014;35:831–5.CrossRefPubMedGoogle Scholar
Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, et al. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene. 2012;31:4559–66.CrossRefPubMedGoogle Scholar
Graziano F, Canestrari E, Loupakis F, Ruzzo A, Galluccio N, et al. Genetic modulation of the Let-7 microRNA binding to KRAS 3′-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan. Pharmacogenomics J. 2010;10:458–64.CrossRefPubMedGoogle Scholar
Smits KM, Paranjape T, Nallur S, Wouters KA, Weijenberg MP, et al. A let-7 microRNA SNP in the KRAS 3′UTR is prognostic in earlystage colorectal cancer. Clin Cancer Res. 2011;17:7723–31.CrossRefPubMedGoogle Scholar
Kjersem JB, Ikdahl T, Guren T, Skovlund E, Sorbye H, et al. Let-7 miRNA-binding site polymorphism in the KRAS 3′UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab. BMC Cancer. 2012;12:534.CrossRefPubMedPubMedCentralGoogle Scholar
Wang WY, Chien YC, Wong YK, Lin YL, Lin JC. Effects of KRAS mutation and polymorphism on the risk and prognosis of oral squamous cell carcinoma. Head Neck. 2012;34:663–6.CrossRefPubMedGoogle Scholar
Li ZH, Pan XM, Han BW, Guo XM, Zhang Z, et al. A let-7 binding site polymorphism rs712 in the KRAS 3′UTR is associated with an increased risk of gastric cancer. Tumour Biol. 2013;34:3159–63.CrossRefPubMedGoogle Scholar
Dai Q, Luo H, Li XP, Huang J, Zhou TJ, Yang ZH. XRCC1 and ERCC1 polymorphisms are related to susceptibility and survival of colorectal cancer in the Chinese population. Mutagenesis. 2015;30:441–9.CrossRefPubMedGoogle Scholar
Bos JL, Fearon ER, Hamilton SR, Verlaan-deVries M, van Boom JH, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature. 1987;327:293–7.CrossRefPubMedGoogle Scholar
Boughdady IS, Kinsella AR, Haboubi NY, Schofield PF. K-ras gene mutations in adenomas and carcinomas of the colon. Surg Oncol. 1992;1:275–82.CrossRefPubMedGoogle Scholar
Hollestelle A, Pelletier C, Hooning M, Crepin E, Schutte M, et al. Prevalence of the variant allele rs61764370 T > G in the 3′UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families. Breast Cancer Res Treat. 2011;128:79–84.CrossRefPubMedGoogle Scholar
Pharoah PD, Palmieri RT, Ramus SJ, Gayther SA, Andrulis IL, et al. The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res. 2011;17:3742–50.CrossRefPubMedPubMedCentralGoogle Scholar
Zhang W, Winder T, Ning Y, Pohl A, Yang D, et al. A let-7 microRNA-binding site polymorphism in 3′-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann Oncol. 2011;22:104–9.CrossRefPubMedGoogle Scholar
Youn CK, Kim MH, Cho HJ, Kim HB, Chang IY, et al. Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents. Cancer Res. 2011;64:4849–57.CrossRefGoogle Scholar
Mishra PJ, Banerjee D, Bertino JR. MiRSNPs or MiR-polymorphisms, new players in microRNA mediated regulation of the cell: introducing microRNA pharmacogenomics. Cell Cycle. 2008;7:853–8.CrossRefPubMedGoogle Scholar